Top 10 Global Clinical Research Organizations in 2021 (Part II)
NO.6 Syneos Health
In 2017, INC Research and Inventiv Health merged to form Syneos Health, which once climbed to the third position in the world.
In 2020, the company’s revenue was 4.42 billion U.S. dollars. It is the only company on the list that has suffered negative growth in performance due to the impact of the new crown virus epidemic, and its ranking has also declined.
NO.7 WuXi
Although WuXi Biologics and WuXi PharmaTech are two independently-operated listed companies, considering that WuXi Biologics originated from WuXi PharmaTech and the chairman of the two companies is the same person, the two companies are referred to as WuXi PharmaTech. Department of consolidated calculations.
WuXi’s business covers all aspects of new drug research and development, almost all-encompassing and omnipotent, and it is already a global giant. Although it has not yet become the global leader, the influence that everyone feels is undoubtedly insurmountable by its peers.
The consolidated revenue of WuXi in 2020 is approximately US$3.26 billion, an increase of 31.4% over 2019. The number of employees reached 32,000. Regardless of income or personnel, the growth rate is far ahead of its peers. And judging from the development trend in recent years, it will still maintain rapid growth.
The negative impact of the new crown virus epidemic on the company is small in scope, mild in severity and short in time. On the contrary, the epidemic has played a major role in promoting performance to some extent. On the one hand, the company has undertaken a number of R&D and production projects related to the new crown virus. On the other hand, the raging overseas epidemic has caused some orders to be transferred to China.
NO.8 Catalent
Catalent was established in 2007, and its expertise is in the production and packaging of preparations, including oral, injection and respiratory administration methods. In fact, the company’s history can be traced back to Scherer, which was established in 1933. The company developed a rotary pressing equipment for soft capsules, which also explains Catalent’s global leadership in soft capsule production. In 2014, the company was listed on the New York Stock Exchange.
Catalent’s full fiscal year is different. Most of them are based on the calendar year, while Catalent is from July to June of the following year. For example, the fiscal year 2020 is from July 2019 to June 2020. The company’s operating income for fiscal year 2020 was US$3.094 billion, a year-on-year increase of 22.89%.
The new coronavirus vaccine developed by Johnson & Johnson is produced by Catalent.
NO.9 Charles River
The company’s business has three main parts: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support. In short, they are animal models, safety evaluation, and production. .
The company’s revenue in 2017 was US$2.92 billion, an increase of nearly 11.5% over the previous year. It has approximately 17,000 employees worldwide.
In 2010, Charles River prepared to acquire WuXi AppTec for a total price of US$1.6 billion. Because the plan was opposed by the company’s shareholders, the agreement had to be unilaterally terminated and WuXi AppTec paid 30 million US dollars for the break-up fee. Since then, WuXi AppTec has firmed its own development path and started a drastic expansion plan with this break-up fee. As the so-called “Hedong in ten years, Hexi in ten years”, Charles River has now been surpassed by WuXi. I don’t know how the shareholders who voted against it felt. Just in time for the sentence: “Yesterday you were indifferent to me, but today I let you not be able to climb high.”
NO.10 Parexel
In 2017, the British private equity firm Pamplona Capital Management announced the completion of the US$5 billion acquisition of Parexel. Parexel subsequently delisted. Since then, its performance has not been announced. Here we refer to the data released in 2018, which is 2.5 billion US dollars and about 19,000 employees. It stands to reason that both figures have increased in the past three years, but the specifics are unknown.
In 2021, the company decided to divest the information system and medical imaging business, which also includes the clinical trial management system, electronic data acquisition system, and registration management system. The new company, Calyx, has 2,300 employees. As a result, Parexel’s revenue and scale will shrink.
In addition to traditional clinical research, Parexel is characterized by the preparation of registration documents and the ability to communicate with the drug administration department. The reason for this feature is that Jingding has a self-developed registration and declaration management system (eCTD software), and that it has established a strong registration and declaration team, of which more than 100 have been in the mainstream pharmaceutical market. Reviewers who have worked in government departments.
Contact Us:
Email : marketing@medicilon.com
Tel : +44 1223 981 792 (Europe)+82 (0)70-8269-5849 (South Korea)
08044216898 (Japan)+86 021 58591500 (China)Website: https://www.medicilon.com
